Global Single Domain Antibody(sdAbs) Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Single Domain Antibody(sdAbs) Drugs market size was valued at US$ 517 million in 2025 and is forecast to a readjusted size of US$ 1132 million by 2032 with a CAGR of 11.6% during review period.
Single Domain Antibody Drugs refer to approved and commercially marketed therapeutic drugs whose active molecules are based on single-domain antibody structures. The currently marketed products mainly include Sanofi's Cablivi, Taisho Pharmaceutical's Nanozora, and Envafolimab manufactured by Alphamab Oncology, covering indications such as acquired thrombotic thrombocytopenic purpura, rheumatoid arthritis, and selected advanced solid tumors. Key upstream inputs include engineered expression cell lines, cell culture media, feeds, single-use bioreactor consumables, chromatography resins, ultrafiltration membranes, buffers, sterile filling components, vials or prefilled syringes, stoppers, labels, and cold-chain packaging materials. Major downstream customers include hospitals, specialty treatment centers, oncology departments, hematology departments, rheumatology and immunology departments, pharmaceutical distributors, and public or commercial reimbursement systems. The 2025 global nominal production capacity is estimated at approximately 1.25 million units, actual sales volume at about 728,000 units, average ex-factory price at around USD 690 per unit, and industry gross margin at approximately 68%–82%.
The single-domain antibody drug market is currently in an early commercialization phase, with clear technological advantages but a limited number of marketed products. Existing drugs mainly target rare diseases, rheumatology, and oncology, showing a small-product, high-margin, and highly differentiated market profile. Differences in indications, administration methods, and patient populations create a dispersed yet finely segmented market structure. As indications expand and more candidate drugs gain approval, the market is expected to gradually grow, although near-term expansion remains centered on currently marketed products and is constrained by regulatory approval and hospital access timelines. The global competitive landscape is highly concentrated, with major manufacturers holding technological barriers and patent protections that confer first-mover advantages. Sanofi, Alphamab Oncology, and Taisho Pharmaceutical occupy leading positions in hematology, oncology immunotherapy, and rheumatology, respectively. New entrants face long R&D timelines, clinical validation requirements, and regulatory hurdles, limiting their ability to capture market share in the short term. Competition focuses on product differentiation, clinical application expansion, and production and supply capabilities, with the commercial model revolving around a small number of high-value patients. Future market growth will be driven by indication expansion of marketed products, regional market access, improvements in reimbursement systems, and potential new drug approvals. The structural characteristics of single-domain antibodies provide advantages in subcutaneous administration, tissue penetration, and multispecific design, potentially increasing penetration in rare diseases and specialized oncology immunotherapy. Technological integration, including AI-assisted discovery, high-throughput screening, and optimization platforms, is expected to improve candidate selection efficiency and developability, supporting market expansion. Key barriers remain the limited number of marketed products, narrow indications, long clinical development cycles, strict regulatory requirements, and small patient populations. Some drugs are derived from non-human structures and require humanization and immunogenicity validation. Although single-domain antibodies offer high technological barriers and innovation value, near-term market expansion is limited, and revenue growth depends on market penetration of existing products, indication expansion, and execution capabilities. Overall, market growth is steady but concentrated in a few core products and manufacturers.
This report is a detailed and comprehensive analysis for global Single Domain Antibody(sdAbs) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Single Domain Antibody(sdAbs) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single Domain Antibody(sdAbs) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single Domain Antibody(sdAbs) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single Domain Antibody(sdAbs) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Single Domain Antibody(sdAbs) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Single Domain Antibody(sdAbs) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Taisho Pharmaceutical, Alphamab Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Single Domain Antibody(sdAbs) Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Cablivi
Nanozora
Envafolimab
Market segment by Administration Route
Subcutaneous Injection
Intravenous Injection
Other
Market segment by Sales Channels
Online Sales
Offline Sales
Market segment by Application
Hospital
Clinic
Other
Major players covered
Sanofi
Taisho Pharmaceutical
Alphamab Oncology
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Single Domain Antibody(sdAbs) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Single Domain Antibody(sdAbs) Drugs, with price, sales quantity, revenue, and global market share of Single Domain Antibody(sdAbs) Drugs from 2021 to 2026.
Chapter 3, the Single Domain Antibody(sdAbs) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Single Domain Antibody(sdAbs) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Single Domain Antibody(sdAbs) Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Single Domain Antibody(sdAbs) Drugs.
Chapter 14 and 15, to describe Single Domain Antibody(sdAbs) Drugs sales channel, distributors, customers, research findings and conclusion.